Design Therapeutics (NASDAQ:DSGN) Posts Earnings Results, Beats Expectations By $0.02 EPS

Design Therapeutics (NASDAQ:DSGN) announced its quarterly earnings data on Monday. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02, Yahoo Finance reports.

Design Therapeutics Price Performance

Shares of DSGN traded down $0.16 during trading hours on Wednesday, hitting $4.05. The stock had a trading volume of 28,077 shares, compared to its average volume of 237,739. The firm has a market capitalization of $228.80 million, a PE ratio of -3.88 and a beta of 1.83. Design Therapeutics has a 12 month low of $1.94 and a 12 month high of $7.83. The stock has a fifty day moving average price of $3.99 and a 200 day moving average price of $3.55.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Royal Bank of Canada reissued a “sector perform” rating and issued a $4.00 target price on shares of Design Therapeutics in a report on Tuesday. Piper Sandler raised Design Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $6.00 to $12.00 in a research report on Tuesday, May 7th. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, Design Therapeutics has a consensus rating of “Hold” and a consensus price target of $6.60.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.